Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Antimetabolites, Antineoplastic
- Analgesics
- Respiratory Tract Infections
- Anti-infective Agents
- Antiviral Agents
- ARDS
- RNA Virus Infections
- Nidovirales Infections
- Coronaviridae Infections
- Coronavirus
- Coronavirus Infection
- Pneumonia, Viral
- Physiological Effects of Drugs
- Severe Acute Respiratory Syndrome Coronavirus 2
- Immunologic Disease
- Immunologic Factors
- Virus Disease
- Lung Diseases
- Pneumonia
- Respiratory Tract Disease
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Phase I will evaluate the safety and efficacy of multiple doses of CYNK-001 (Days 1,4, and 7) in 14 patients. Phase II will utilize a randomized, open-label design; multiple doses of CYNK-001 will be compared to the control group: Best Supportive Care. Up to 72 patients will be included in the Phase II portion of the study with a 1:1 randomization ratio.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04365101
- Collaborators
- IDRI
- Lung Biotechnology PBC
- California Institute for Regenerative Medicine (CIRM)
- Investigators
- Principal Investigator: Corey Casper, MD MPH IDRI
Get Well Soon